The party drug ketamine can have powerful beneficial effects on severely depressed patients who have struggled for years to recover, and the drug should be developed responsibly as a psychiatric medicine, British experts said on Thursday.
In a study published in the Lancet Psychiatry journal, specialists from Oxford University said there is an urgent need for ethical and innovative action by doctors to prescribe the drug under controlled conditions.
"We think patients' treatment should be in specialist centres and formally tracked in national or international registries," said Rupert McShane, a consultant psychiatrist and researcher at Oxford who has led a series of ketamine studies.
Ketamine is a licensed medical drug, widely used as an anaesthetic and to relieve pain. But it is also used as a recreational drug — sometimes known as Special K — and can lead some people into addiction and drug abuse.
Several research teams around the world have been trialling ketamine use in chronic and recurring depression, since many patients with the psychiatric condition fail to respond to currently available antidepressants such as Prozac and Seroxat.
"I have seen ketamine work where nothing has helped before," McShane said at a briefing in London.
The U.S. pharmaceutical company Johnson & Johnson is developing an intranasal form of the drug, called esketamine. Its results so far have been promising enough for U.S. Food and Drug Administration officials to speed its progress through regulatory hurdles.
McShane and his co-researcher Ilina Singh, a psychiatry professor at Oxford University, told the briefing there had been a worrying sharp rise in the past year in the number of private ketamine clinics in the United States.
There are wide variations in the clinical checks before a patient receives treatment, they said, and there is a need for clear guidelines and registries to track how patients respond.
Last month, the American Psychiatric Association issued a consensus statement on ketamine in a bid to guide safe, appropriate prescribing of the drug for severe patients who do not respond to regular antidepressants.
McShane stressed that the ketamine doses used in the Oxford depression treatment trials are given in controlled conditions and are very different from those taken by street or club users.
On the street, users often take several grams a day and can suffer severe bladder problems and impaired brain function. The doses used in medical trials are a fraction of that — around 80 milligrams — and given once a week in a monitored setting.
Singh said ketamine has such great potential to help a small group of very ill patients that it would be wrong not to find a way of allowing them to benefit from it: "This drug is available, it's out there, and if we can help patients get treatment responsibly, it's our duty to do so," she said.
Treating patients in specialist centres should help doctors spot potential problems early, she said, as well as picking up any abuse problems with longer term use and narrowing down what dose, frequency, route and duration of treatment works best.
Latest USA News
- Sharing stories from here, our home
- Refugee's success shows potential of young newcomers
- Ready to launch
- Private practice
- Ferry held hostage until First Nation's problems addressed
- Blue stroll over watered-down Esks
- Time, fire erase last visible ties to community builder
- Former gridiron standout Idonije writes stories encouraging youngsters to be the best they can be
- Former attorney general Roland Penner dead at 93
- Playbook: Caps take 2-1 Cup series lead, Tkachuk a hot NHL prospect, Tiger lurking at Memorial and more...
- Mental illness cited in deaths of Steinbach father and son
- Brrrrr-utal! Spring temperatures likely weeks away
- Wheeler, muckers lead way to victory
- Civil trials moving at brisker pace
- Taking a stand against harassment
- City eyes traffic lights at site of fatal collision
- Winnipeg has love affair with horror
- Waste not, want not
- A valuable space, lost in litigation
- Free Press Head Start for April 3
- Secret life of plants making music
- Ex-Hydro chairman refutes premier
- Wire-to-wire world champ
- Optimism shines bright at upbeat Juno Awards show in Vancouver
- Canada joins U.S., Europe in expelling Russian spies for British poison attack
- Feds ease restrictions on prescription heroin to address opioid epidemic
- Mexico official: Iowa family died from water heater gas leak
- White House: Trump thinks Stormy Daniels lied about threat
- Developer to alter Pembina Highway apartment plans
- It's a great time to be a sports fan in Winnipeg
- He has the answers
- Manitoba announces operators of legal cannabis stores
- Feds to help Churchill residents pay high cost of gas
- Journalism still necessary in Canada: survey
- Getting into the weeds
- A call for justice
- Family, friends gather to protest reduced sentences for young offenders convicted of killing Serena McKay
- Two people dead in fatal trailer fire in Grand Rapids
- 200 mourners attend funeral for boy killed at crosswalk
- Jets penalty killing third-best in the league